Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone

被引：22

作者：

Buysschaert, M ^{[1
]}

Bobbioni, E ^{[1
]}

Starkie, M ^{[1
]}

Frith, L ^{[1
]}

Van Gaal, L ^{[1
]}

Somers, G ^{[1
]}

Reynders, P ^{[1
]}

Buysschaert, M ^{[1
]}

Bouillon, R ^{[1
]}

Johansen, J ^{[1
]}

Gilehuus, RE ^{[1
]}

Furuseth, K ^{[1
]}

Hansen, AN ^{[1
]}

Luhdbo, C ^{[1
]}

Caldeira, J ^{[1
]}

Saraiva, M ^{[1
]}

Correa, N ^{[1
]}

Medina, L ^{[1
]}

Silva, JL ^{[1
]}

Robertson, L ^{[1
]}

Lourens, W ^{[1
]}

Bonnici, F ^{[1
]}

Distiller, L ^{[1
]}

Ellis, G ^{[1
]}

Gomez, F ^{[1
]}

Golay, A ^{[1
]}

Suter, S ^{[1
]}

Harrower, ADB ^{[1
]}

Rayman, G ^{[1
]}

Shaw, I ^{[1
]}

Simpson, HCR ^{[1
]}

Johnston, C ^{[1
]}

White, M ^{[1
]}

Hepburn, DA ^{[1
]}

Beer, SF ^{[1
]}

Leatherdale, BA ^{[1
]}

Coppack, S ^{[1
]}

Hamill, JJ ^{[1
]}

Fisher, BM ^{[1
]}

机构：

[1] Univ Catholique Louvain, Clin Univ St Luc, Serv Endocrinol & Nutr, B-1200 Brussels, Belgium

来源：

DIABETIC MEDICINE | 1999年 / 16卷 / 02期

关键词：

combination therapy; glycaemic control; sulphonylurea; troglitazone; Type 2 diabetes mellitus;

D O I：

10.1046/j.1464-5491.1999.00029.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aim The aim of this study was to investigate the effectiveness of troglitazone (a peroxisome proliferator-activated receptor-gamma agonist developed primarily for the treatment of Type 2 diabetes mellitus (DM)), 100 or 200 mg/day, in terms of glycaemic control, lipid profile and tolerability, when given in addition to existing sulphonylurea therapy. Methods A 16-week, randomized, parallel-group placebo-controlled trial in 259 Type 2 diabetic patients already on sulphonylurea therapy. Results At week 16, adjusted geometric mean HbA1c with troglitazone 100 mg (7.7%; P = 0.023) and 200 mg (7.4%; P < 0.001) was lower with sulphonylurea alone (8.2%). At all weeks, adjusted geometric mean fasting serum glucose levels were lower in both troglitazone groups, compared with sulphonylurea alone (P = 0.007 to P < 0.001). At week 16, both troglitazone groups showed reductions in immune reactive insulin compared with sulphonylurea alone (200 mg, 13%; P = 0.032: 100 mg, 5%; NS), Troglitazone reduced serum levels of nonesterified fatty acids at week 16 (100 mg, 12%; P = 0.042) and at all weeks (200 mg, 17 - 24%; P = 0.014 to P < 0.001). The incidence of drug-related adverse events was similar in all groups (23-24% of patients). There was no apparent association between hypoglycaemia and the addition of troglitazone to sulphonylurea therapy. Conclusions Troglitazone 100 or 200 mg added to usual sulphonylurea therapy in patients with Type 2 DM is associated with a significant improvement in glycaemic control, without altering the adverse-event profile of the sulphonylurea.

引用

页码：147 / 153

页数：7

共 15 条

[11] Effects of troglitazone and metformin on glucose and lipid metabolism - Alterations of two distinct molecular pathways [J].

Lenhard, JM ;

Kliewer, SA ;

Paulik, MA ;

Plunket, KD ;

Lehmann, JM ;

Weiel, JE .

BIOCHEMICAL PHARMACOLOGY, 1997, 54 (07) :801-808

[12] Double-masked, placebo-controlled, dose-ranging study of troglitazone 10 to 200 mg once daily in non-insulin-dependent diabetes mellitus [J].

Leutenegger, M ;

Sacca, L ;

Alderton, C ;

Eckland, D ;

Lettis, S .

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1997, 58 (07) :403-416

[13]

Levin K, 1997, ENDOCRINOL METAB, V4, P255

[14] Effect of troglitazone in insulin-treated patients with type II diabetes mellitus [J].

Schwartz, S ;

Raskin, P ;

Fonseca, V ;

Graveline, JF .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) :861-866

[15]

YOUNG MA, 1998, IN PRESS ANN MED

← 1 2 →